Drug intelligence / Profile preview

AST-Cp-13

Development stage: Preclinical
Lead developer: ASTRA Therapeutics
Modality: Small Molecules

Overview

AST-Cp-13 is a discovery-stage small molecule parasiticide being developed by ASTRA Therapeutics for the treatment of protozoan infections in companion animals. Discovered using ASTRA's proprietary ParaX® drug development platform, AST-Cp-13 belongs to a novel class of species-specific parasite inhibitors known as Parabulins®. The drug is designed to selectively target and inhibit parasite tubulin, disrupting microtubule dynamics and cell division in the pathogen while sparing the host animal's cells. AST-Cp-13 is currently in the discovery phase of development.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on AST-Cp-13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-Cp-13.

Explore the full profile